Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer
To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case-cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n=9,349). Until the end of follow-up (1 January 1996), 397 postmenopausal breast canc...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2003-05, Vol.88 (9), p.1394-1399 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1399 |
|---|---|
| container_issue | 9 |
| container_start_page | 1394 |
| container_title | British journal of cancer |
| container_volume | 88 |
| creator | ONLAND-MORET, N. C KAAKS, R VAN NOORD, P. A. H RINALDI, S KEY, T GROBBEE, D. E PEETERS, P. H. M |
| description | To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case-cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n=9,349). Until the end of follow-up (1 January 1996), 397 postmenopausal breast cancer cases were identified and a subcohort of 424 women was then taken from all eligible women. Women using hormones were excluded, leaving 364 breast cancer cases and 382 women in the subcohort for the analyses. Concentrations of oestrone, oestradiol, testosterone, 5alpha-androstane-3alpha, 17beta-diol and creatinine were measured in first morning urine samples, which had been stored since enrolment at -20 degrees C. A Cox proportional Hazards model was used, with Barlow's adjustment for case-cohort sampling, to estimate breast cancer risk in quartiles of each of the, creatinine corrected, hormone levels, the lowest quartile being the reference group. Women with higher levels of all four of the hormones were at increased risk for postmenopausal breast cancer (highest vs lowest quartile: incidence rate ratio for oestrone (IRR(oestrone)=2.5, 95% CI: 1.6-3.8; IRR(oestradiol)=1.5, 95% CI: 1.0-2.3; IRR(testosterone)=1.6, 95% CI: 1.0-2.4; IRR(5alpha-androstane-3alpha, 17beta-diol)=1.7, 95% CI: 1.1-2.7). In conclusion, women with higher excretion levels of both oestrogens and androgens have an increased risk of breast cancer. |
| doi_str_mv | 10.1038/sj.bjc.6600890 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2741036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73329477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-3fc47578575c66c2fff510d55d7766a5fb03b660b97604cf7f62a14caa512c753</originalsourceid><addsrcrecordid>eNpdkdFr1TAUxoNM3HX66psjCO6t1yRtctoXQYZuwkAQ9xzSNNlt1yZ3Oe2Y_72RWzf1KYT88p3zfR8hbzjbclbWH3DYtoPdKsVY3bBnZMNlKQpeCzgiG8YYFKwR7Ji8RBzytWE1vCDHXADUTMGGfL9OfTDpJ3WhizcuxAUpuge6i2mKwdHR3bsRqQkdnXeOph5vafR0H3GeMr03C5qRtskZnKk1wbr0ijz3ZkT3ej1PyPWXzz_OL4urbxdfzz9dFbZSci5KbyuQUEuQVikrvPeSs07KDkApI33Lyjb7ahtQrLIevBKGV9YYyYUFWZ6Qjwfd_dJOrrMuzMmMep_6KRvS0fT635fQ7_RNvNcCqpydygJnq0CKd4vDWU89WjeOJricg4ayFE0FkMF3_4FDXFLI5rQQTVM3QrAMbQ-QTRExOf-4CWf6d1caB5270mtX-cPp3_s_4Ws5GXi_AgatGX3K8fb4xOX46jw4c28PXDDzktwj8GfQLxi7qDk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229989220</pqid></control><display><type>article</type><title>Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>ONLAND-MORET, N. C ; KAAKS, R ; VAN NOORD, P. A. H ; RINALDI, S ; KEY, T ; GROBBEE, D. E ; PEETERS, P. H. M</creator><creatorcontrib>ONLAND-MORET, N. C ; KAAKS, R ; VAN NOORD, P. A. H ; RINALDI, S ; KEY, T ; GROBBEE, D. E ; PEETERS, P. H. M</creatorcontrib><description>To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case-cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n=9,349). Until the end of follow-up (1 January 1996), 397 postmenopausal breast cancer cases were identified and a subcohort of 424 women was then taken from all eligible women. Women using hormones were excluded, leaving 364 breast cancer cases and 382 women in the subcohort for the analyses. Concentrations of oestrone, oestradiol, testosterone, 5alpha-androstane-3alpha, 17beta-diol and creatinine were measured in first morning urine samples, which had been stored since enrolment at -20 degrees C. A Cox proportional Hazards model was used, with Barlow's adjustment for case-cohort sampling, to estimate breast cancer risk in quartiles of each of the, creatinine corrected, hormone levels, the lowest quartile being the reference group. Women with higher levels of all four of the hormones were at increased risk for postmenopausal breast cancer (highest vs lowest quartile: incidence rate ratio for oestrone (IRR(oestrone)=2.5, 95% CI: 1.6-3.8; IRR(oestradiol)=1.5, 95% CI: 1.0-2.3; IRR(testosterone)=1.6, 95% CI: 1.0-2.4; IRR(5alpha-androstane-3alpha, 17beta-diol)=1.7, 95% CI: 1.1-2.7). In conclusion, women with higher excretion levels of both oestrogens and androgens have an increased risk of breast cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6600890</identifier><identifier>PMID: 12778067</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Breast Neoplasms - epidemiology ; Cohort Studies ; Epidemiology ; Estradiol - urine ; Estrone - urine ; Female ; Follow-Up Studies ; France - epidemiology ; Gonadal Steroid Hormones - urine ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Postmenopause ; Risk Factors ; Testosterone - urine ; Time Factors ; Tumors</subject><ispartof>British journal of cancer, 2003-05, Vol.88 (9), p.1394-1399</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Nature Publishing Group May 6, 2003</rights><rights>Copyright © 2003 Cancer Research UK 2003 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-3fc47578575c66c2fff510d55d7766a5fb03b660b97604cf7f62a14caa512c753</citedby><cites>FETCH-LOGICAL-c465t-3fc47578575c66c2fff510d55d7766a5fb03b660b97604cf7f62a14caa512c753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741036/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741036/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,2728,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14758203$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12778067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ONLAND-MORET, N. C</creatorcontrib><creatorcontrib>KAAKS, R</creatorcontrib><creatorcontrib>VAN NOORD, P. A. H</creatorcontrib><creatorcontrib>RINALDI, S</creatorcontrib><creatorcontrib>KEY, T</creatorcontrib><creatorcontrib>GROBBEE, D. E</creatorcontrib><creatorcontrib>PEETERS, P. H. M</creatorcontrib><title>Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case-cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n=9,349). Until the end of follow-up (1 January 1996), 397 postmenopausal breast cancer cases were identified and a subcohort of 424 women was then taken from all eligible women. Women using hormones were excluded, leaving 364 breast cancer cases and 382 women in the subcohort for the analyses. Concentrations of oestrone, oestradiol, testosterone, 5alpha-androstane-3alpha, 17beta-diol and creatinine were measured in first morning urine samples, which had been stored since enrolment at -20 degrees C. A Cox proportional Hazards model was used, with Barlow's adjustment for case-cohort sampling, to estimate breast cancer risk in quartiles of each of the, creatinine corrected, hormone levels, the lowest quartile being the reference group. Women with higher levels of all four of the hormones were at increased risk for postmenopausal breast cancer (highest vs lowest quartile: incidence rate ratio for oestrone (IRR(oestrone)=2.5, 95% CI: 1.6-3.8; IRR(oestradiol)=1.5, 95% CI: 1.0-2.3; IRR(testosterone)=1.6, 95% CI: 1.0-2.4; IRR(5alpha-androstane-3alpha, 17beta-diol)=1.7, 95% CI: 1.1-2.7). In conclusion, women with higher excretion levels of both oestrogens and androgens have an increased risk of breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Cohort Studies</subject><subject>Epidemiology</subject><subject>Estradiol - urine</subject><subject>Estrone - urine</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>France - epidemiology</subject><subject>Gonadal Steroid Hormones - urine</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Postmenopause</subject><subject>Risk Factors</subject><subject>Testosterone - urine</subject><subject>Time Factors</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkdFr1TAUxoNM3HX66psjCO6t1yRtctoXQYZuwkAQ9xzSNNlt1yZ3Oe2Y_72RWzf1KYT88p3zfR8hbzjbclbWH3DYtoPdKsVY3bBnZMNlKQpeCzgiG8YYFKwR7Ji8RBzytWE1vCDHXADUTMGGfL9OfTDpJ3WhizcuxAUpuge6i2mKwdHR3bsRqQkdnXeOph5vafR0H3GeMr03C5qRtskZnKk1wbr0ijz3ZkT3ej1PyPWXzz_OL4urbxdfzz9dFbZSci5KbyuQUEuQVikrvPeSs07KDkApI33Lyjb7ahtQrLIevBKGV9YYyYUFWZ6Qjwfd_dJOrrMuzMmMep_6KRvS0fT635fQ7_RNvNcCqpydygJnq0CKd4vDWU89WjeOJricg4ayFE0FkMF3_4FDXFLI5rQQTVM3QrAMbQ-QTRExOf-4CWf6d1caB5270mtX-cPp3_s_4Ws5GXi_AgatGX3K8fb4xOX46jw4c28PXDDzktwj8GfQLxi7qDk</recordid><startdate>20030506</startdate><enddate>20030506</enddate><creator>ONLAND-MORET, N. C</creator><creator>KAAKS, R</creator><creator>VAN NOORD, P. A. H</creator><creator>RINALDI, S</creator><creator>KEY, T</creator><creator>GROBBEE, D. E</creator><creator>PEETERS, P. H. M</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20030506</creationdate><title>Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer</title><author>ONLAND-MORET, N. C ; KAAKS, R ; VAN NOORD, P. A. H ; RINALDI, S ; KEY, T ; GROBBEE, D. E ; PEETERS, P. H. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-3fc47578575c66c2fff510d55d7766a5fb03b660b97604cf7f62a14caa512c753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Cohort Studies</topic><topic>Epidemiology</topic><topic>Estradiol - urine</topic><topic>Estrone - urine</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>France - epidemiology</topic><topic>Gonadal Steroid Hormones - urine</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Postmenopause</topic><topic>Risk Factors</topic><topic>Testosterone - urine</topic><topic>Time Factors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ONLAND-MORET, N. C</creatorcontrib><creatorcontrib>KAAKS, R</creatorcontrib><creatorcontrib>VAN NOORD, P. A. H</creatorcontrib><creatorcontrib>RINALDI, S</creatorcontrib><creatorcontrib>KEY, T</creatorcontrib><creatorcontrib>GROBBEE, D. E</creatorcontrib><creatorcontrib>PEETERS, P. H. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ONLAND-MORET, N. C</au><au>KAAKS, R</au><au>VAN NOORD, P. A. H</au><au>RINALDI, S</au><au>KEY, T</au><au>GROBBEE, D. E</au><au>PEETERS, P. H. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>2003-05-06</date><risdate>2003</risdate><volume>88</volume><issue>9</issue><spage>1394</spage><epage>1399</epage><pages>1394-1399</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>To assess the relation between urinary endogenous sex steroid levels and the risk of postmenopausal breast cancer, a nested case-cohort study was conducted within a large cohort (the DOM cohort) in the Netherlands (n=9,349). Until the end of follow-up (1 January 1996), 397 postmenopausal breast cancer cases were identified and a subcohort of 424 women was then taken from all eligible women. Women using hormones were excluded, leaving 364 breast cancer cases and 382 women in the subcohort for the analyses. Concentrations of oestrone, oestradiol, testosterone, 5alpha-androstane-3alpha, 17beta-diol and creatinine were measured in first morning urine samples, which had been stored since enrolment at -20 degrees C. A Cox proportional Hazards model was used, with Barlow's adjustment for case-cohort sampling, to estimate breast cancer risk in quartiles of each of the, creatinine corrected, hormone levels, the lowest quartile being the reference group. Women with higher levels of all four of the hormones were at increased risk for postmenopausal breast cancer (highest vs lowest quartile: incidence rate ratio for oestrone (IRR(oestrone)=2.5, 95% CI: 1.6-3.8; IRR(oestradiol)=1.5, 95% CI: 1.0-2.3; IRR(testosterone)=1.6, 95% CI: 1.0-2.4; IRR(5alpha-androstane-3alpha, 17beta-diol)=1.7, 95% CI: 1.1-2.7). In conclusion, women with higher excretion levels of both oestrogens and androgens have an increased risk of breast cancer.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>12778067</pmid><doi>10.1038/sj.bjc.6600890</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2003-05, Vol.88 (9), p.1394-1399 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2741036 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Biological and medical sciences Breast Neoplasms - epidemiology Cohort Studies Epidemiology Estradiol - urine Estrone - urine Female Follow-Up Studies France - epidemiology Gonadal Steroid Hormones - urine Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Postmenopause Risk Factors Testosterone - urine Time Factors Tumors |
| title | Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T14%3A44%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20endogenous%20sex%20hormone%20levels%20and%20the%20risk%20of%20postmenopausal%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=ONLAND-MORET,%20N.%20C&rft.date=2003-05-06&rft.volume=88&rft.issue=9&rft.spage=1394&rft.epage=1399&rft.pages=1394-1399&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6600890&rft_dat=%3Cproquest_pubme%3E73329477%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229989220&rft_id=info:pmid/12778067&rfr_iscdi=true |